The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

Are substance-induced psychosis and primary psychosis fundamentally different? And if they are, does it matter?

Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

Significant weight gain is a common side effect of many psychiatric medications. Fortunately, there are options for those who ...

"Bob Dean would have been completely protected," said one advocate about how the law change would affect nursing home ...

A Delray Beach man pleaded guilty to conspiracy to commit wire fraud for his role in a national scheme to distribute ...

We published the book "Demystifying Psychiatry" in 2010. Although basic principles of psychiatric treatment remain unchanged, ...

Gardiner Harris’s investigation of Johnson & Johnson explores the many ways corporate greed and weak regulations fail to ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly ...